Alcohol use disorder (AUD) is a highly prevalent but severely under-treated disorder, with
only three widely-approved pharmacotherapies. Given that AUD is a very heterogeneous …

Baclofen is an effective therapeutic for the treatment of spasticity related to multiple sclerosis,
spinal cord injuries, and other spinal cord pathologies. It has been increasingly used off …

The lack of reliable measures of alcohol intake is a major obstacle to the diagnosis and
treatment of alcohol-related diseases. Epigenetic modifications such as DNA methylation …

Abstract γ-aminobutyric acid type B (GABA B) receptors are broadly expressed in the
nervous system and play an important role in neuronal excitability. GABA B receptors are G …

Adaptation of the nervous system to different chemical and physiologic conditions is
important for the homeostasis of brain processes and for learning and remembering …

Alcohol use disorder is a leading cause of morbidity and mortality. 1–2 Alcohol consumption
is related to approximately 4% of the global burden of disease. 1 In clinical settings and …

Aims Alcohol dependence is a major public health issue with a need for new
pharmacological treatments. The ALPADIR study assessed the efficacy and safety of …

Previous randomized, placebo-controlled trials (RCTs) assessing the efficacy of the
selective γ-aminobutyric acid (GABA)-B receptor agonist baclofen in the treatment of alcohol …

Background Alcohol use disorder (AUD) and alcoholrelated impairments belong to the
most widespread psychiatric disorders leading to specific psychophysical, affective and …

Alcohol use disorder (AUD) is a brain disorder associated with high rates of mortality and
morbidity worldwide. Baclofen, a selective gamma-aminobutyric acid-B (GABA-B) receptor …